⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

September 24, 2025International Journal of Dermatology

Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System

Tung S Tran Duc V. Le James Jacobs Trang M Nguyen David A. Wetter Giang Huong Nguyen

View at Publisher

Ask AI

Bookmark

Share

Key Points

Bimekizumab shows safety data in psoriasis patients from FDA's adverse event reporting system, indicating monitoring needs.
Pharmacovigilance data reveal insights into adverse events associated with bimekizumab in patients treated for psoriasis.
Assessment of FDA adverse event reports provides crucial information for understanding drug safety in real-world settings.
The findings highlight the importance of ongoing monitoring of treatment safety in managing psoriasis patients.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Pharmacovigilance data assess safety of bimekizumab in psoriasis patients, suggesting potential concerns.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tran et al. (2025) studied this question.

synapsesocial.com/papers/68d6c687b1249cec298b2a60 https://doi.org/10.1111/ijd.70082

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Real-world single-centre experience of bimekizumab in patients with psoriasis: a 16-week retrospective observational studyCohort Study · 2026
2Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse EventsOriginal Research · 2025 · 17 citations
3Rapid and sustained improvement of psoriasis with Bimekizumab: A real‐world case series2024
4Bimekizumab efficacy and safety in Chinese patients with psoriasis in the <scp>BE SHINING</scp> Phase 3 studyRCT · 2026
5Efficacy and tolerability of bimekizumab within patients with moderate-to-severe plaque psoriasis: learnings from real world evidence2025 · 1 citations
6Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trialsMeta-Analysis · 2023 · 8 citations
7Evaluating the Efficacy and Safety of Bimekizumab for Plaque Psoriasis and Psoriatic Arthritis: An Expert Consensus Panel Report2024
8Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials2024 · 15 citations
9Diagnostic Features of Cutaneous Micromelanoma (≤ 6 mm): A Systematic Review and Meta‐AnalysisInternational Journal of Dermatology · 2026
10Interpreting Keloidal Scarring in Dissecting Cellulitis of the ScalpInternational Journal of Dermatology · 2026

More from International Journal of Dermatology

More from Mayo Clinic

More from Hanoi Medical University

More from Bassett Medical Center

More from National Hospital of Pediatrics